Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 -0.0518518518518518 -0.125925925925926
Stock impact report

Acorda Therapeutics Q4 revenues up 34%; updates guidance [Seeking Alpha]

Acorda Therapeutics, Inc. (ACOR) 
Last acorda therapeutics, inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acorda.com/investors
Company Research Source: Seeking Alpha
Acorda Therapeutics Q4 revenues up 34%; updates guidanceAcorda Therapeutics (ACOR)Q4 results: Revenues: $188.4M (+34.0%); Operating Loss: ($218.1M); Net Loss: ($171.1M); Loss Per Share: ($3.70); Non-GAAP EPS: $0.61; Quick Assets: $307.1M (+93.8%).2018 Guidance: AMPYRA Net Revenue: $330M - 350M; R&D expenses: $100M - 110M; SG&A expenses: $170M - 180M.Click to subscribe to real-time analytics on ACORNow read:Doubling Survival Time For Pancreatic Cancer - ARMO BioSciences » Show less Read more
Impact Snapshot
Event Time:
ACOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ACOR alerts
Opt-in for
ACOR alerts

from News Quantified
Opt-in for
ACOR alerts

from News Quantified